JAZZ

Jazz Pharmaceuticals Plc 2009 10-K Summary

Business Context and Reporting Period

This Annual Report on Form 10-K covers the fiscal year ended December 31, 2009. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on neurology, psychiatry, and pain management. The company markets two primary products: Xyrem (sodium oxybate) for narcolepsy and Luvox CR (fluvoxamine maleate) for obsessive compulsive disorder and social anxiety disorder. A key development milestone in 2009 was the submission of a New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia, which was filed by the FDA in February 2010.

Key Financial Metrics

Revenue Breakdown (2009): Xyrem net sales were $96.8 million (84% of product sales), and Luvox CR net sales were $18.3 million (16% of product sales). Contract revenues increased significantly to $11.1 million, driven by a $10.0 million milestone payment from UCB Pharma related to JZP-6.

Material Changes vs. Prior Period

• Profitability Improvement: The company significantly reduced its net loss from $184.3 million in 2008 to $6.8 million in 2009. This was driven by a 78% increase in product sales and a 47% reduction in selling, general, and administrative (SG&A) expenses.
• Expense Reduction: SG&A expenses dropped from $111.4 million to $58.7 million, primarily due to a reduction in the sales force size in late 2008 and lower marketing costs for Luvox CR following its 2008 launch. Research and Development (R&D) expenses decreased 48% to $36.6 million as the company focused resources on the JZP-6 NDA submission.
• Debt Restructuring: In 2009, the company experienced defaults on its Senior Secured Notes due to missed interest payments and failure to maintain a restricted cash balance. These defaults were cured in July 2009 following a private placement of equity. In November 2009, the Senior Note Agreement was amended to include quarterly principal amortization payments starting in 2010.
• Intangible Assets: Unlike 2008, which included a $29.8 million impairment charge for Luvox CR, 2009 had no impairment charges. However, the useful life of the Luvox CR intangible asset was shortened to 2.7 years due to generic competition risks.

Guidance, Outlook, and Risks

Outlook: Management expects 2010 product sales to be higher than 2009, primarily due to price increases on Xyrem implemented in late 2009. The company plans to fund operations for the next 12 months through existing cash, operating cash flow, and its revolving line of credit. Beyond 12 months, the company anticipates needing additional capital to fund the potential launch of JZP-6, Phase IV clinical trials for Luvox CR, and debt repayment.

Key Risks and Contingencies:

• Debt Maturity: The company has $119.5 million in Senior Secured Notes maturing in June 2011, with significant principal payments due in 2010. Failure to refinance or repay could lead to acceleration of debt.
• Supply Chain Constraints: The sole supplier of sodium oxybate (Lonza) announced the closure of its U.S. facility. The company faces risks regarding DEA quotas and the qualification of new suppliers, which could impact the supply of Xyrem and JZP-6.
• Regulatory Approval: The commercial future of JZP-6 depends on FDA approval of the NDA filed in December 2009. Approval is not guaranteed, and a required Risk Evaluation and Mitigation Strategy (REMS) could limit market access.
• Generic Competition: The company is engaged in patent litigation with Actavis and Anchen regarding generic versions of Luvox CR. Additionally, orphan drug exclusivity for Xyrem's cataplexy indication expired in July 2009.
• Liquidity: The company has a history of net losses and relies on product sales growth to meet obligations. If sales do not meet expectations, the company may need to raise additional capital on dilutive terms.

Investor Verification Checklist

• Debt Service Capability: Verify the company's ability to meet the $40 million in principal payments due on Senior Notes in 2010 and the remaining $79.5 million due in June 2011.
• JZP-6 FDA Decision: Monitor the FDA's review timeline and decision on the JZP-6 NDA for fibromyalgia, as this is the primary growth catalyst.
• Supply Chain Transition: Confirm the status of securing a new supplier for sodium oxybate and obtaining necessary DEA quotas to prevent shortages of Xyrem.
• Luvox CR Litigation: Track the outcome of the patent infringement lawsuits against Actavis and Anchen to assess the risk of generic entry.
• Cash Burn Rate: Review quarterly cash flow statements to ensure operating cash generation is sufficient to cover debt service and R&D costs without immediate dilutive financing.